Ms. Samira Sakhia reports

KNIGHT THERAPEUTICS ANNOUNCES RELAUNCH OF ORGOVYX® IN CANADA

Knight Therapeutics Inc. has relaunched Orgovyx (relugolix) in Canada.

In June, 2024, Knight and Sumitomo Pharma America Inc. (SMPA) announced that Knight and SMPA's affiliates had entered into exclusive licence and supply agreements to commercialize Myfembree (relugolix/estradiol/norethindrone acetate), Orgovyx (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight acquired certain mature products.

Orgovyx (relugolix) is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by Health Canada for the treatment of adult patients with advanced prostate cancer. Orgovyx was approved in October, 2023, and launched in March, 2024. In February, 2025, the pan-Canadian Pharmaceutical Alliance (pCPA) negotiations were concluded successfully and Orgovyx has since received public listing in most provinces across Canada. Orgovyx competes in the GnRH (gonadotropin-releasing hormone) agonist and antagonist market for prostate cancer, which, based on IQVIA, is valued at over $200-million and has been growing at a five-year CAGR (compound annual growth rate) of 8 per cent.

"Orgovyx offers health care professionals a convenient oral alternative to rapidly suppress testosterone production for patients with prostate cancer. This new therapeutic option empowers clinicians to align treatment with each patient's unique needs, helping optimize the best possible outcomes," said Samira Sakhia, president and chief executive officer of Knight. "Orgovyx is synergistic with our existing oncology portfolio with Trelstar and will allow Knight to leverage our existing infrastructure."

About Orgovyx (relugolix)

Orgovyx (relugolix 120 mg tablets) is the first and only oral GnRH receptor antagonist approved by Health Canada for the treatment of adult patients with advanced prostate cancer. As a GnRH antagonist, Orgovyx blocks the pituitary GnRH receptor, thereby reducing the release of the luteinizing and follicle-stimulating hormones, and consequently reducing the production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer. According to IQVIA, sales of Orgovyx in Canada were approximately $1.2-million in 2024.

About Knight Therapeutics Inc.

Knight Therapeutics, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics' shares trade on Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.